The aim of the study: to investigate an interrelationship between pre-treatment gfalcetin-3 level and one-year survival rate in subjects with chronic lymphocytic leukemia Methods: One hundred fifty six subjects with chronic lymphocytic leukemia were enrolled in the study. Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=63) and a no statin group (n=83). Among the 63 patients in the statin group, 39 patients received 20-mg/day atorvastatin and 24 patients received 40-mg/day atorvastatin. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of Gal-3, IL-6 and and NT-pro-brain natriuretic peptide (BNP) were used. Concentrations of Gal-3 and NT-pro-BNP for cumulative survival rate were tested. Results: Within 1 year 30 CV events were reported, i.e. 11 events (25.6%) were exhibited in statin users and 19 events (41.3%) were documented in never statin users (Chi2=2.66; P<0.001). Lipid lowering effect in statin user was associates with declined serum Gal-3 level, whereas in not statin users similar response was 24 Borys B. Samura not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Univariate logistic regression had exhibited that Gal-3 (odds ratio [OR] = 1.13; 95% CI = 1.07-1.25; P = 0.003), NT-proBNP (OR=1.05; 95% CI = 1.03-1.08; P = 0.001) and statin therapy (OR=1.06; 95% CI = 1.01-1.10; P = 0.001) predicted one-year cumulative CV events. After adjustment on statin therapy, Gal-3 remained independent predictor one-year cumulative cardiovascular events (OR = 1.07; 95% CI = 1.05-1.10; p = 0.001). When initial serum Gal-3 level has incorporated into prediction Model, statin therapy was found as predictor for improving survival in CLL patients with elevated serum Gal-3 level (>14 ng/ml). Conclusion: Elevated pre-treatment galectin-3 level was found a powerful predictor of positive effect of statins on survival in patients with chronic lymphocytic leukemia.
Introduction
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progression by displaying intracellular and extracellular activities [1] . Increased expression of galectin-3 (Gal-3) has been associated with chronic myelogenous leukemia, multiple myeloma and chronic lymphocytic leukemia (CLL) [2] . Higher representation of Gal-3 mRNA was observed in indolent CLL patients compared with the progressive group [3] . Although modern treatment options for CLL produce high response rates, the interrelation between elevated Gal-3 and survival rate is not fully understood. Moreover, elevated Gal-3 associates with increased cardiovascular (CV) risk [4] . In this context there is possibility to use statins in dyslipidemic stable CLL patients to prevent unfavorable CV outcomes under control of Gal-3 level.
The aim of the study: to investigate an interrelationship between pre-treatment gfalcetin-3 level and one-year survival rate in subjects with chronic lymphocytic leukemia
Design and Methods
One hundred fifty six out subjects with full or partial remission of chronic lymphocytic leukemia were enrolled in the study. All subjects gave their written informed consent to participation in the study. Diagnosis and staging of lymphoproliferative diseases were defined by current clinical practice guidelines [1, 2] . To be achieving remission chemotherapy with FC, R-FC, R-CHOP, CHOP, Galectin-3 as predictor of higher statin treatment 25 mini-CHOP, COP, was used accordingly contemporary clinical guidelines. All subjects were at full or partial remission stage at baseline The characteristic of entire group of the enrolled patients has presented recently [3] . Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=63) and no statin group (n=83). Only patients with dyslipidemia were treated with statins. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Of the 63 patients in the statin group, 39 patients received 20-mg/day atorvastatin and 24 patients received 40-mg/day atorvastatin. Echocardiography in B-mode was performed accordingly to Recommendation of American Society of Echocardiography on the scanner "MyLab 50" (Italy) using a transducer with a frequency of 2.5-3.5 MHz. End-diastolic and end-systolic LV volumes were obtained using a two-dimensional reference sector according to Simpson's method, and LV ejection fraction (LVEF) was calculated by accordingly conventional methods [4] .
Clinical Events: Screening and Diagnostics
Clinical interviews were carried out every month for three years after baseline. The following are the clinical events verified: newly diagnosed strokes or TIAs; death for any reasons and sudden cardiac death; coronary ischemic events (myocardial infarction, unstable angina) that needed hospital admission for cardiovascular reasons, new-onset chronic heart failure. Newly diagnosed strokes were confirmed with CT. All clinical events were presented as cumulative
Blood sampling
All blood samples were collected after fasting in cooling vacutainer and after that it was immediately centrifuged (4°C for 6.000 × 15 min). After centrifugation serum was blind coded and stored at -70° until used. Human Gal-3, IL-6 and NTproBNP were measured by ELISA technique (ELISA kits manufactured by R&G, United Kingdom) used for examination. All determinations were done by duplicating. Fasting plasma glucose (FPG) was quantified by the glucose oxidase procedure; HbA1c was measured by ion-exchange high-performance liquid chromatography (HPLC; Bio-Rad, Hercules, CA, USA). Concentrations of total cholesterol (TC), low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol were determined by direct enzymatic methods using Dimension Clinical Chemistry System (Dade Behring Inc, Newark, NJ). All measurements and blood sample for were collected at the same visit.
Statistics
All statistical analyses were performed in SPSS for Windows v. 17.0 (SPSS Inc., Chicago, IL, USA). All values were given as mean and 95% confidence interval
[CI] or median and percentiles. An independent group t-test was used for comparisons for all interval parameters meeting the criteria of normality and homogeneity of variance. For interval parameters not meeting these criteria, the non-paramentric Mann-Whitney test was used to make comparisons between the groups. Comparisons of categorical variables between the groups were performed using the Chi2 test, and the Fisher exact test. The potential factors that may be associated with cardiovascular events was identified first by the univariate analysis, then multivariate logistic regression analyses were used to identify the predict factors. A calculated difference of P<0.05 was considered significant.
Results
The baseline characteristic of both cohorts of the patients depending treatment regime is presented in the Table 1 . All patients were matched accordingly age, sex, CV complications, diabetes presentation rate, serum biomarker concentration, and concomitant medications. Note: * -statistically differences between parameters in the two groups (P<0.05); CI -confidence interval; T2DM -type two diabetes mellitus, GFR -Glomerular filtration rate, BMI -Body mass index, BNP -brain natriuretic peptide, ACEIangiotensin-converting enzyme inhibitor, ARAs -angiotensin-2 receptors antagonists.
All of the patients in the statin group tolerated the treatment well, and no serious side-effects were reported during the follow-up period. The effect of both statin regimes is reported in the Table 2 . One can see, lipid lowering effect in statin user was associates with declined serum Gal-3 level, whereas in not statin users similar response was not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Table 3 is reported characteristics of the CLL patients with vs without CV events.
One can see, free-events subjects had lover levels of Gal-3 and NT-proBNP than subjects with CV events. Univariate logistic regression had exhibited that Gal-3 (odds ratio [OR] = 1.13; 95% CI = 1.07-1.25; P = 0.003), NT-proBNP (OR=1.05; 95% CI = 1.03-1.08; P = 0.001) and statin therapy (OR=1.06; 95% CI = 1.01-1.10; P = 0.001) predicted one-year cumulative CV events. After adjustment on statin therapy, Gal-3 remained independent predictor one-year cumulative cardiovascular events (OR = 1.07; 95% CI = 1.05-1.10; p = 0.001). When initial serum Gal-3 level has incorporated into prediction Model, statin therapy was found as predictor for improving survival in CLL patients with elevated serum Gal-3 level (>14 ng/ml). The results of the study have confirmed an assumption regarding statins' positive effect on survival in higher risk subjects with CLL. Although this is a preliminary result, probably, it is required more investigations to explain the role of pretreatment level of Gal-3 as independent predictor of long-term clinical outcomes in stable individuals with CLL.
Conclusion
The results of the study have exhibited that elevated pre-treatment galectin-3 level might be a powerful predictor of positive effect of statins on survival in patients with chronic lymphocytic leukemia.
